Beijing-listed Tong Ren Tang Technologies Co. Ltd. (Tong Ren Tang Technologies) disclosed the audited 2025 results of its Hong Kong subsidiary Beijing Tong Ren Tang Chinese Medicine Company Limited (Tong Ren Tang Chinese Medicine), revealing softer top-line performance and compressed margins.
Revenue and Profitability • Revenue slipped 6.10% year on year to HK$1.51 billion, pressured by slower sales momentum. • Gross profit fell 13.10% to HK$0.93 billion, driving the gross margin down to 61.18% from 66.09% in 2024. • Operating profit declined 18.17% to HK$0.47 billion, with the margin contracting to 31.23% (2024: 35.80%). • Net profit attributable to owners dropped 20.57% to HK$0.40 billion, translating to basic and diluted EPS of HK$0.47 (-22.04%).
Cost and Expense Movements • Distribution and selling expenses decreased 31.02% to HK$0.21 billion, reflecting tighter cost control. • General and administrative expenses edged down 4.43% to HK$0.18 billion. • Impairment losses on financial assets surged to HK$0.06 billion from HK$0.00 billion, weighing on earnings.
Balance Sheet Highlights • Cash and cash equivalents climbed 25.60% to HK$2.23 billion, underpinned by stronger liquidity. • Inventories contracted 15.56% to HK$1.34 billion, signalling inventory optimisation efforts. • Total assets stood at HK$4.66 billion, while total equity reached HK$4.37 billion, equating to an equity ratio of 93.74%.
Comprehensive Income Total comprehensive income attributable to owners amounted to HK$0.40 billion, down 16.66% year on year, mainly due to earnings contraction despite a HK$7.45 million positive currency translation swing.
Dividend and Outlook The announcement contained no dividend proposal or forward-looking guidance.
Corporate Structure Tong Ren Tang Chinese Medicine is listed on the Main Board of the Hong Kong Stock Exchange (stock code: 3613) and remains a consolidated subsidiary of Tong Ren Tang Technologies (stock code: 01666).
The board of Tong Ren Tang Technologies released the above information on 20 March 2026 in accordance with Hong Kong disclosure requirements.